Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cabaletta Bio ( (CABA) ) has provided an announcement.
On March 23, 2026, Cabaletta Bio reported fourth-quarter and full-year 2025 results and outlined progress on rese-cel, its lead CAR T therapy for autoimmune diseases. The company said its RESET-Myositis registrational cohort is enrolling 17 dermatomyositis and antisynthetase patients, with data intended to support a myositis BLA filing targeted for 2027.
Cabaletta highlighted advancing innovations, including a no-preconditioning regimen in lupus and pemphigus vulgaris and automated rese-cel manufacturing via Cellares’ Cell Shuttle, with initial clinical data across these initiatives expected in the first half of 2026. It also plans to present complete Phase 1/2 data from RESET-SLE, RESET-SSc and RESET-MG in 2026 to guide FDA discussions on registrational pathways, while its $133.6 million year-end 2025 cash balance, supplemented by $30 million raised in early 2026, is expected to fund operations into the fourth quarter of 2026.
The most recent analyst rating on (CABA) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, expanding losses, and heavy cash burn that elevates funding risk). Offsetting factors include strong recent technical momentum and positive corporate developments around registrational progress and manufacturing readiness, but valuation remains constrained by ongoing losses.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio, Inc. is a late-stage clinical biotechnology company developing targeted cell therapies for autoimmune diseases, aiming for deep, durable, potentially curative treatments. Its lead CARTA program centers on rese-cel, a fully human CD19 CAR T-cell therapy being tested across rheumatology, neurology and dermatology in the RESET clinical development program, with headquarters and labs in Philadelphia, Pa.
Average Trading Volume: 3,015,337
Technical Sentiment Signal: Buy
Current Market Cap: $283M
Find detailed analytics on CABA stock on TipRanks’ Stock Analysis page.